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Background – It remains unclear for how long the benefits of pulmonary rehabilitation (PR) 
last in interstitial lung disease (ILD).  An increasing number of ILD patients complete PR and 
it is vital they be offered the most beneficial approaches. 
Methods – This is a retrospective, observational study of a cohort with ILD who had 
completed PR.  Incremental shuttle walk (ISWT) and chronic respiratory disease 
questionnaire (CRDQ) were compared before PR, at course completion, and 6/12 months 
follow-up.  Focus group discussions with ILD participants who had completed PR and their 
carers established qualitative views on existing and potential future PR provision. 
Results – 79 participants with ILD were identified at course completion, with 39 followed to 
12 months.  11 participants died during follow-up.  Initial benefits from PR were not 
sustained at 6 months (ISWT change 0.0m (95% CI -23.2 to 23.2m), CRDQ change 2.5 (95% CI 
-2.4 to 7.4)) and 12 months (ISWT change -0.7m (95% CI -37.3 to 35.9m), CRDQ change 4.0 
(95% CI -2.2 to 10.2)).  Continued home exercise gave longer lasting benefit in exercise 
capacity.  Focus group discussions highlighted the value attached to PR and suggested areas 
for improvement. 
Conclusions – Standard PR gives initial benefits in participants with ILD who complete the 
course, however these are not sustained.  Tailored approaches to this group would be 
appreciated by this group and should be explored. 
  





Duration of benefit following completion of Pulmonary Rehabilitation in Interstitial Lung 
Disease – an observational study 
Introduction 
Disabling breathlessness frequently complicates Interstitial Lung Diseases (ILDs).  Patients 
report significantly limited activities of daily living, along with low levels of physical 
functioning and high levels of fatigue and dyspnoea
1
.  These limitations contribute to 
significantly reduced quality of life (QoL)
2
.  While pharmacological treatments are now 
available for IPF
3, 4
 and other ILDs
5, 6
, their impact on QoL is unclear.  International 
guidelines
7, 8
 advocate referral for pulmonary rehabilitation (PR), while the UK NICE quality 
standard for IPF highlights its importance
9
. PR is well established in Chronic Obstructive 
Pulmonary Disease (COPD)
10
 but evidence of benefit in ILD patient populations is of low 
quality
11, 12
. Limited data exists concerning longer term benefit from PR in this group.  This is 
especially important given the greater likelihood of progressive deterioration in participants 
with ILD. 
We report a retrospective, observational study of a well characterised population of 
consecutive patients with ILD who completed a PR course.  To capture patient/carer 
experience and attitudes towards PR in ILD, we conducted focus group discussions with 
those who had completed PR. 
The aims of this study were:  
1) Determine if there is a sustained benefit from PR in ILD. 
2) Identify patient characteristics associated with response to PR in ILD.  
3) Undertake a qualitative assessment of PR experience in ILD. 





We considered that this would help to inform future ILD-tailored PR programmes.   
Methods  
Study subjects 
The Lung Education and Exercise Programme (LEEP) at North Bristol NHS Trust has over 20 
years’ experience providing a standard PR course to a heterogeneous population.  
Increasingly, referrals come from Bristol Interstitial Lung Disease (BILD) service; 10-15% of 
those completing PR have ILD. 
We retrospectively identified consecutive participants with a diagnosis of ILD made by their 
referring physician, who completed PR from the LEEP database.   Outcomes were recorded 
at course completion, and at follow-up visits after 6 and 12 months.  
Study ethical approval was granted by NRES Committee East of England - Cambridge South 
(REC reference 15/EE/0023). 
Pulmonary Rehabilitation programme 
LEEP is a PR programme, for all respiratory diagnoses, conforming to standard BTS 
recommendations
11
.  The six week course includes twice-weekly sessions, with an 
educational component and supervised, monitored exercise and a third home exercise 
session, all tailored to participants according to their needs and disease severity.  Exercise 
prescriptions for each participant are based on their medical history and exercise capacity, 
including upper and lower extremity training and incorporating both strength and 
endurance elements.  
Measures 






Baseline variables included diagnosis, age, gender, co-morbidities, smoking history and 
pulmonary function tests.   
Exercise capacity 
An Endurance Shuttle Walk Test (ESWT) and an Incremental Shuttle Walk Distance (ISWT) 
were performed at pre-course assessment according to published American Thoracic 
Society/European Respiratory Society field walking test criteria
13
.  At each follow-up visit, 
ISWT was repeated, as per standard practice for the LEEP course.  ISWT has been used in 
previous studies and appears responsive to PR in ILD
14, 15
. Participants used oxygen or 
walking aids if required.   
Health Status, Mood & Dyspnoea 
Change was assessed in the Chronic Respiratory Disease Questionnaire (CRDQ), a 20-item 
questionnaire covering domains of dyspnoea, mastery, emotion and fatigue, which has been 




.  Higher scores represent more 
severe disease.  The minimal clinically important difference (MCID) of 10 points was used as 
previously described
17
.  The Hospital Anxiety and Depression Score (HADS) was used to 
assess anxiety and depression
18
; this is a 14-item questionnaire with higher scores 
representing more severe symptoms.  Breathlessness was measured using Medical Research 
Council (MRC) dyspnoea scores. 
Patient focus groups  
A thematic content analysis approach was taken for this study, using semi-structured focus 
group discussions conducted with a convenience sample of subjects, identified and 





approached at a bi-monthly patient support group.  Group discussions lasted one hour and 
were moderated by a male physician (CS) and a female ILD specialist nurse (HL) and 
recorded by detailed field notes.  Both moderators were known to the group participants.  
Topics focused on patient and carer experiences of PR and areas which may improve these 
experiences.  Questions and discussion points used are shown in Supplemental table S1.  
The two moderators (CS and HL) independently agreed that data saturation had been 
achieved. 
In qualitative analysis, field notes were reviewed for an overall impression.  Candidate 
themes were identified and grouped.  Descriptions were prepared based on these themes 
and presented as results.  Results were discussed between the study authors. 
Statistical analysis 
Data are described using mean with standard deviation (SD) or mean difference with 95% 
confidence intervals (CI) unless otherwise indicated.  Continuous variables were compared 
using t-tests.  Categorical variables were compared using χ
2
 tests.  To assess the impact of 
PR on course completion and at follow-up visits (6 and 12 months), each visit was compared 
to the pre-course values.  Sensitivity analyses following multiple imputation of missing cases 
were performed to assess the impact of loss to follow-up over the study period.  Multiple 
imputation was not used in the remainder of the analyses. 
Multiple linear regression models were constructed to ascertain predictive elements from 
amongst the baseline characteristics. Collinearity was assessed and ESWT, pulmonary 
function and baseline HADS were excluded from the model.   
Data were analysed using SPSS software (v23.0.0; IBM Corp.; Armonk, NY, USA). 









We identified 79 consecutive patients with ILD who completed PR from the LEEP database.  
Demographics are shown in Table 1, diagnoses in Table 2. The most common diagnosis was 
IPF (n=28, 35.4%).  Patients had moderate physiological and functional impairment, with 
mean baseline Forced Vital Capacity (FVC) 75.6% predicted (SD 22.6%) and Diffusing 
Capacity for Carbon Monoxide (DLCO) 47.2% predicted (SD 18.8%).  25.9% of participants had 
a decline in FVC of >10% in the year prior to course participation. There were no differences 
for FVC or FEV1/FVC ratio between ILD diagnostic groups (Supplemental table S3).  ILD 
participants with potentially obstructive physiology did not significantly differ from others in 
this cohort.  Baseline ISWT was 177.4m (SD 110.9m) and patients had poor QoL with mean 
CRDQ, 78.3 (SD 18.4).  Other baseline measurements are shown in Table 1.  
Completion of follow-up is shown in Figure 1; data were available for 52 participants at 6 
months following course completion and 39 participants at 12 months.  11 participants died 
during 12 months follow-up.  Sensitivity analyses suggested no significant impact on overall 
findings with loss to follow-up (Supplemental table S2).  Amongst those lost, there was no 
significant difference in baseline ISWT compared to those completing 12 months’ follow-up 
(difference 42.8m (95% CI -95.29m to +9.72m), p=0.11). 
Short term impact of PR 





PR was effective in ILD for those who completed the course, improving both ISWT and CRDQ 
(Figure 2).  ISWT improved by a mean of 29.5m (95% CI 13.7 to 45.2m).  CRDQ improved by 
11.6 (95% CI 8.5 to 14.7).  38 participants (48.7%) achieved the MCID of a 10 point 
improvement.  Pre-course HADS values indicated no clinical depression or anxiety and did 
not change after PR.  Effects were similar between the subgroups of patients with IPF and 
non-IPF ILDs (Supplemental table S3).  There was no difference in response to PR between 
participants with and without progressive FVC decline (>10%) before the course (Difference 
in ISWT change 38.2m, p=0.101, difference in CRDQ change 1.95, p=0.647). 
Long term impact of PR 
Benefits of PR were not sustained at 6 months or 12 months for participants with ILD 
following course completion (Figure 2).  There was no difference between subgroups of 
participants with IPF and non-IPF diagnoses in mean change in ISWT from baseline at 6 or 12 
months (0.0m (95% CI -23.2 to 23.2m) and -0.7m (95% CI -37.3 to 35.9m) respectively).  
Analyses were repeated excluding those lost to follow-up; the values did not significantly 
change.  There was no difference in ISWT change at 6 months between participants with 
and without progressive FVC decline before the course (Difference in ISWT change 4.5m, 
p=0.882). 
Initial improvements in CRDQ were not sustained, with mean change from baseline at 6 
months of 2.5 (95% CI -2.4 to 7.4) and at 12 months of 4.0 (95% CI -2.2 to 10.2).  At 6 and 12 
months, 31.2% and 29.6% of participants achieved the MCID. There was no difference in 
CRDQ change at 6 months between participants with and without progressive FVC decline 
before the course (Difference in CRDQ change 9.36, p=0.193). 





Of those completing 6 months’ follow-up, 58.3% reported continuing with their home 
exercise prescription, while 29.2% continued to attend a weekly supervised exercise session.  
At 12 months, these numbers reduced to 39.3% and 10.7% respectively.  Those reporting 
having discontinued home exercise were more likely to experience a fall in their ISWT at 6 
months (-27.4m vs 18.6m, 95% CI for the difference 0.1m to 91.8m, p=0.049).  There were 
no other differences between those reporting continued home exercise, or those attending 
regular supervised exercise sessions (Figure 3). 
Prediction of response to PR 
A multiple linear regression model predicted 17.4% of the variance in ISWT change 6 
months following course completion, F(3,46)=3.026, p=0.04.  Co-efficients of variables 
included in the model are reported in Table 3.  Shorter baseline ISWT (β=-0.368, p=0.026), 
and younger age (β=-0.386, p=0.016) were predictive of more sustained improvement in 
ISWT at 6 months.   
A similar model constructed for improvement in CRDQ at 6-month follow-up, predicted 
16.6% of the variance, F(3,47)=2.929, p=0.044.  Co-efficients of variables included in the 
model are shown in Table 4.  A lower pre-course CRDQ was predictive of greater 
improvement in QoL at 6 months (β=-0.432, p=0.008). 
Focus group discussions 
Twenty-three patients and 20 carers participated in focus group discussions, with a range of 
ILD diagnoses and aged between 62 and 83 years (15 male, 8 female).  No patients or carers 
who were approached declined to participate. Analysis of discussions identified several 
themes. 





Experiences of PR 
All felt that PR was valuable, with particular importance being attached to social elements of 
the course and its role in reducing feelings of isolation.  Some negative views were 
expressed; many felt there was insufficient time for exercise, however this was debated 
within the focus group.  Overall the course was felt to be too short.  There was also concern 
over the predominance of COPD, with patients reporting feeling distinct and isolated from 
the group, along with feelings of stigma due to oxygen use.  Many patients expressed 
anxiety about unsupervised exercise after PR. 
Suggestions for development of PR in ILD 
Patient and carer suggestions to improve PR for those with ILD included: 
• Longer sessions to give more time for exercise 
• Longer course duration 
• To enable carers to be present for at least some of the course, to benefit from the 
educational component.  Carers were especially keen on this idea 
• Ongoing supervised exercise sessions after course completion 
• Specific ILD focused lectures and content more tailored to ILD concerns including 









In this analysis of real-world delivery of standard PR for participants with a variety of ILDs 
following course completion, we observed initial benefits in exercise capacity and health 
status. Improvements in exercise capacity and health status were not sustained to 6 
months.  Patients and carers with ILD felt that PR is a valuable component of their disease 
management, but could be improved.  
These observations suggest this group benefits from PR.  The regression analyses to identify 
predictors of benefit offer conflicting results, with greater benefits seen where PR is 
delivered in more severe disease as assessed by exercise capacity, but in those with less 
impairment to QoL and at a younger age.  
We acknowledge limitations to this study.  We followed patients from completion of PR.  
Therefore these results can only be generalised to ILD patients completing PR.  There was 
also loss of participants to follow-up in this observational study, reflecting real-world 
conditions.  Subject characteristics did not significantly differ between those lost and those 
completing follow-up.  Additionally, sensitivity analyses demonstrated that this did not 
change our findings.  Any bias is likely to be towards over-stating the degree of benefit in 
this study, as those not completing PR or subsequent follow-up may have more severe 
disease.  As such this adds weight to our conclusion that benefits of PR are not sustained in 
ILD. 
These limitations are balanced by the real-world world relevance and generalisability of a 
significant population with one of the longest periods of follow up reported.  We were able 
to enrich our analysis using focus group discussions to capture patient experiences of PR.  









While PR is recognised to have a sustained response in participants with COPD
20
, the current 
literature is inconclusive regarding duration of benefit of PR in ILD.  A recent meta-analysis 
of randomised, controlled trials (RCTs) of standard PR programmes in ILD demonstrated 
short term effectiveness in both walking distance and QoL
12
.  Reports conflict on how 
sustained this benefit is.   
Ryerson et al reported benefit sustained above the MCID to 6 months in walking distance, 
but not for QoL or dyspnoea in a cohort study
21
.  A small RCT by Vainshelboim showed no 
differences between groups at 11 months
22
.  In a cohort study, Holland et al indicated that 
improvements in walking distance and QoL were not sustained
23
.  Kozu et al compared 
patients with IPF with a cohort with COPD, demonstrating only modest short term gains, not 
sustained on 6-month follow-up
24
.  Ochmann et al examined the effect of PR in occupational 
lung diseases and found that while exercise capacity benefits were sustained on 12-month 
follow-up for asthma and COPD, benefit was not sustained beyond 3 months in silicosis and 
asbestosis
25
.  The long term efficacy of standard PR in ILD remains unproven.  
In keeping with our observations of the benefits of continued exercise, Dalichau has 
demonstrated preserved benefit in a cohort of asbestosis patients to 18 months where they 
continued exercise, with loss of benefit where exercise was ceased
26, 27
. 
Data surrounding predictors of response to PR in ILD are conflicting.  Previous work has 
suggested a reduced response to PR in a more severe, oxygen dependent group, as 
compared to those with no such requirement
14
, while Holland et al observed maximum 
benefit in those with milder disease
23
.  In contrast, Ferreira et al observed reduced response 
in those with greater baseline exercise capacity
28
 and Ryerson et al reported that greatest 
benefit was seen in those with the most severe impairment
21
.  Our data also conflict. It 





appears appropriate to offer PR to ILD patients of all but the most severe levels of 
impairment, which would preclude course completion.  
Our heterogeneous cohort of ILD patients did not demonstrate any differential response to 
PR when separated by diagnosis, however there is some evidence to suggest that patients 
with IPF are most likely to benefit
29
.  An important question for future work will be to 
identify which groups benefit most. 
Tailoring of PR courses to ILD patients’ needs is an area which needs further exploration.  
Strength and endurance are impaired in fibrotic lung diseases
30, 31
, however endurance 
responds well to PR
32
.  The need to sustain activity and exercise beyond the end of the 
course is highlighted by more sustained improvements observed in those continuing home 
exercise to 6-month follow-up.  It is possible, however, that a failure to sustain such activity 
is a marker of pulmonary decline.  Guidelines have advocated the importance of the 
educational component to patients’ self-efficacy
33
, however at present course content is not 
tailored to patients’ diseases.  This was important to the focus group participants, and also 
in work conducted by the British Lung Foundation, who found that 28% of IPF patients 
surveyed found their PR to be of average quality or worse and 98% would appreciate a 
tailored approach
34
.   
Summary 
Despite initial benefits from PR, overall improvements are not sustained in participants with 
ILD following course completion.  Focus group discussions indicate that a tailored, ILD-
specific programme would be valued. This is an area in which no quantitative data have 
been produced and there is a pressing need for a robust, large scale, randomised trial to test 
this question.   
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 Table 1 – Baseline demographic, physiological and quality of life values, Interstitial Lung 
Disease participants 
 Mean/Value SD 
Age (years) 68.8 11.9 
Male (%) 55.7  
Smoking history (%) Ex-smoker 60.8  
 Never smoked 39.2  
 Current smoker 0  
Comorbidities (%) None 38.0  
 1-2 45.1  
 3 or more 16.9  
Death <12 months (%) 13.9  
Follow-up (months) 32.3 25.5 
FEV1 % predicted 74.9 21.5 
FVC % predicted 75.6 22.6 
DLCO % predicted 47.2 18.8 
TLC % predicted 69.6 18.8 
Incremental Shuttle Walk Distance (m) 177.4 110.9 
Endurance Shuttle Walk Distance (s) 329.2 286.4 
MRC score 3.3 1.0 
CRDQ overall   78.3 18.4 
  Mastery 18.4 5.2 
  Emotion 31.9 8.6 
  Fatigue 13.8 4.5 
  Dyspnoea 14.1 5.0 
HADS overall   12.6 6.6 
  Anxiety 6.4 4.0 
  Depression 6.2 3.3 
Abbreviations – FVC (Forced Vital Capacity), FEV1 (Forced Expiratory Volume in 1 second), 
TLC (Total Lung Capacity), DLCO (Diffusing Capacity for Carbon Monoxide) 
 
  





 Table 2 – Diagnoses of participants 
Diagnosis n % 
Idiopathic Pulmonary Fibrosis 28 35.4 
Asbestosis 10 12.7 
Hypersensitivity Pneumonitis 8 10.1 
Idiopathic Non-Specific Interstitial Pneumonia 8 10.1 
Sarcoid 8 10.1 
Combined Pulmonary Fibrosis and Emphysema 5 6.3 
Connective Tissue Disease-related ILD 4 5.1 
Respiratory Bronchiolitis-ILD 3 3.8 
Drug induced ILD 2 2.5 
Rheumatoid Arthritis with Usual Interstitial Pneumonia 2 2.5 
Lymphangioleiomyomatosis 1 1.3 
Total 79 100 
 
  





Table 3 – Co-efficients of variables in multiple linear regression model for change in ISWT 






 Beta Beta   
(Constant) 142.22  1.693 0.098 
Age (years) -2.849 -0.386 -2.518 0.016 
Baseline ISWT -0.266 -0.368 -2.307 0.026 
Baseline CRDQ 1.35 0.316 2.011 0.051 
Dependent Variable: Change in ISWT at 6 months 
Abbreviations – Incremental Shuttle Walk Test (ISWT), Chronic Respiratory Disease 
Questionnaire score (CRDQ) 
 
  





 Table 4 - Co-efficients of variables in multiple linear regression model for change in CRDQ 
at 6 month follow-up 
Model Unstandardized Coefficients Standardized 
Coefficients 
t Sig. 
 Beta Beta   
(Constant) 29.612  1.646 0.107 
Age (years) -0.001 -0.001 -0.005 0.996 
Baseline ISWT 0.023 0.150 0.956 0.344 
Baseline CRDQ -0.397 -0.432 -2.798 0.008 
Dependent Variable: Change in CRDQ at 6 months 
Abbreviations – Incremental Shuttle Walk Test (ISWT), Chronic Respiratory Disease 
Questionnaire score (CRDQ) 
 
 








Study flow diagram  
Figure 1  
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Change in exercise capacity and quality of life on follow-up. 
ISWT - Incremental Shuttle Walk Test, CRDQ - Chronic Respiratory Disease Questionnaire, MCID - Minimal 
Clinically Important Difference  
Figure 2  
110x36mm (600 x 600 DPI)  
 
 








Impact of continued home exercise on quality of life and exercise capacity. 
ISWT - Incremental Shuttle Walk Test, CRDQ - Chronic Respiratory Disease Questionnaire, MCID - Minimal 
Clinically Important Difference  
Figure 3  
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Table S1 – Focus group questions and discussion points 
 
How useful did you find the pulmonary rehabilitation course? 
 
What limitations did you find as a patient with lung fibrosis? 
 
Was the educational part of the course relevant to you? 
 
What could be done to improve the course for patients with interstitial lung disease? 
 
If you could design a course for patients with lung fibrosis, what would you include?  How long 
would the sessions and the course in general last? 
 
 
Table S2 - Summary of missing value analysis estimated means and standard deviations (SD) 

























All Values Mean 68.8 26.2 510 .0 -0.8 11.7 2.5 
SD 11.9 68.3 494 79.1 96.2 13.5 16.9 
Expectation 
maximisation 
Mean 68.78 26.2 517 2.7 -1.6 11.6 2.4 
SD 11.9 67.8 496 78.6 95.6 13.8 17.0 
Regression Mean 68.78 25.3 529 0.9 -11.5 11.7 1.0 
SD 11.9 66.5 493 75.9 104.6 13.8 16.5 










Table S3 – Baseline characteristics of participants with IPF and Non-IPF ILD 









p value for 
comparison 
 Mean SD Mean SD   
Age (years) 66.33 13.08 73.25 7.63 2.27 11.56 <0.01 




   0.04 
Smoking history (n (%))  
Ex-smoker 30 (58.8) 18 (64.3)  0.63 
Never smoked 21 (41.2) 10 (35.7)   
Current smoker 0 (0) 0 (0)   
Death <12 months (n (%)) 3 (5.9) 8 (28.6)  0.01 
Followup (months) 36.20 27.59 25.25 19.86 -21.69 -0.21 0.05 
FEV1 % predicted 75.20 23.16 74.38 18.10 -10.63 8.99 0.88 
FVC % predicted 78.14 23.84 70.46 19.31 -17.99 2.63 0.14 
DLCO % predicted 51.11 19.57 39.24 14.37 -20.35 -3.39 0.01 
TLC % predicted 75.37 18.93 59.76 14.04 -24.69 -6.53 <0.01 
FVC trend prior to PR (% 
decline/yr) 
1.05 17.03 -6.45 7.56 -13.97 -1.02 0.02 
DLCO trend prior to PR (% 
decline/yr) 
1.88 17.09 -5.91 10.57 -15.28 -0.30 0.04 
ISWT (m) 186.47 115.15 159.62 101.80 -78.26 24.55 0.30 
MRC score 3.20 0.98 3.61 0.96 -0.43 0.87 0.08 
CRDQ overall 77.08 17.24 80.39 20.44 -5.32 11.94 0.47 
Mastery 18.16 4.84 18.96 5.79 -1.78 3.4 0.53 
Emotion 30.92 8.24 33.75 8.95 -1.28 6.94 0.17 
Fatigue 13.47 4.11 14.25 5.28 -1.54 3.1 0.50 
Dyspnoea 14.53 5.41 13.43 4.23 -3.3 1.1 0.32 
HADS overall 13.16 6.34 11.54 7.05 -4.83 1.59 0.316 
Anxiety 6.98 4.01 5.43 3.96 -3.43 0.32 0.103 
Depression 6.18 3.07 6.11 3.61 -1.69 1.55 0.932 
Abbreviations – FVC (Forced Vital Capacity), FEV1 (Forced Expiratory Volume in 1 second), TLC 
(Total Lung Capacity), DLCO (Diffusing Capacity for Carbon Monoxide), ISWT (Incremental 
Shuttle Walk Test), CRDQ (Chronic Respiratory Disease Questionnaire), HADS (Hospital Anxiety 
and Depression Score) 
 





List of abbreviations 
QoL – Quality of Life 
ILD – Interstitial lung disease 
IPF – Idiopathic Pulmonary Fibrosis 
PR – Pulmonary Rehabilitation 
NICE – National Institute for Health and Care Excellence 
COPD – Chronic Obstructive Pulmonary Disease 
LEEP – Lung Education and Exercise Programme 
BTS – British Thoracic Society 
ESWT – Endurance Shuttle Walk Test 
ISWT – Incremental Shuttle Walk Test 
CRDQ – Chronic Respiratory Disease Questionnaire 
MCID – Minimal clinically important difference 
HADS – Hospital Anxiety and Depression Score 
MRC – Medical Research Council 
SD – Standard Deviation 
CI – Confidence Interval 
FVC – Forced Vital Capacity 
DLCO – Diffusing Capacity for Carbon Monoxide 
FEV1 – Forced Expiratory Volume in 1 second 
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